Quince Therapeutics, Inc. Earnings Per Share Disclosure
Note 13. Net Loss per Share
Basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average common shares outstanding during the period, as follows (net loss in thousands):
|
Years Ended December 31, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Numerator: |
|
|
|
|
|
||
Net loss |
$ |
(83,979 |
) |
|
$ |
(56,828 |
) |
Denominator: |
|
|
|
|
|
||
Weighted average common shares outstanding |
|
50,096,897 |
|
|
|
43,262,269 |
|
Net loss per share, basic and diluted |
$ |
(1.68 |
) |
|
$ |
(1.31 |
) |
The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented because including them would have been antidilutive:
|
December 31, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Stock options issued and outstanding |
|
12,794,855 |
|
|
|
9,905,150 |
|
Common warrants |
|
8,671,928 |
|
|
|
— |
|
Pre-Funded warrants |
|
2,000,000 |
|
|
|
— |
|
Restricted stock awards |
|
— |
|
|
|
78,417 |
|
Total |
|
23,466,783 |
|
|
|
9,983,567 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Apr 10, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
| 2023 | Apr 1, 2024 | |
| 2022 | Mar 15, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.